At 6:31 yesterday morning, at University Hospital in Coventry, Margaret Keenan, who turns 91 next week, received the first dose of the Pfizer-BioNTech COVID-19 vaccine as part of the UK's vaccination programme. The UK regulator authorised the vaccine on December 2, the first country to do so after the results of a large trial. The US Food and Drug Administration is expected to decide in the next few days.

It is one of the most hopeful moments of a hard year. It also starts one of the largest exercises in rationing in modern times. For months, there will be far fewer doses than people who want them. Somebody has to decide who goes first, and every answer means that somebody else waits.

That makes vaccine allocation a very practical question of moral philosophy. This post looks at the main ethical principles in play, how the UK and the US have applied them, the arguments still going on, and what the debate can teach anyone who has to share out something scarce.

1. The principles in tension

Most ethical frameworks for allocating scarce medical resources draw on a small set of values. The World Health Organization's SAGE values framework, published in September, and the US National Academies' framework, published in October, both use versions of them.

Principle What it asks Who it tends to prioritise
Maximise benefit Which allocation saves the most lives or years of life? People at highest risk of dying, or people most likely to spread the virus
Equal moral concern Does every person's life count equally? Resists ranking people by social value
Priority to the worst off Who is most disadvantaged? Groups with higher exposure, poorer health or less access to care
Reciprocity Who has taken on extra risk for others? Health and care workers
Instrumental value Whose work keeps society functioning? Essential workers
Legitimacy and transparency Is the process open, consistent and accountable? Not a group, but a requirement for public trust

These principles do not give a single answer. They describe what any answer should weigh.

2. The UK answer: start with those most likely to die

The UK's Joint Committee on Vaccination and Immunisation (JCVI) published its final advice on December 2. The list is mostly about age:

  1. Residents in care homes for older adults and their carers.
  2. People aged 80 and over, and frontline health and social care workers.
  3. People aged 75 and over.
  4. People aged 70 and over, and people who are clinically extremely vulnerable.
  5. Then people aged 65 and over, adults under 65 with underlying health conditions, and finally people aged 60, 55 and 50 and over.

The JCVI estimates that these groups together account for around 99 percent of preventable deaths from COVID-19. The ordering follows the number of people who would need to be vaccinated to prevent one death, based on UK data from earlier in the year.

This is a broadly utilitarian approach: the main goal is to prevent as many deaths as possible, as quickly as possible. It is also simple to run. Age is easy to verify, hard to fake and does not require anyone to judge whose job is more important.

3. The US debate: older people or essential workers?

In the US, the Advisory Committee on Immunization Practices (ACIP) voted 13 to 1 on December 1 that the first doses should go to health care personnel and residents of long-term care facilities. That part was not very controversial.

The harder question is who comes next, and it has opened a real disagreement.

The case for older adults first is the same as the UK's: they are much more likely to be hospitalised and to die. Vaccinating them saves the most lives directly.

The case for essential workers first draws on other principles. Grocery staff, meat packers, transit workers and teachers cannot stay at home. Older people, at least those who are not in care homes, can often reduce their exposure more easily. In the US, Black and Hispanic workers are over-represented in many essential jobs, and those communities have suffered higher death rates. Prioritising them can be seen as giving priority to the worst off, and as reciprocity for the risks they have been taking all year.

There is also an empirical question underneath the moral one. Modelling discussed in the US debate suggests that vaccinating older adults first averts slightly more deaths, while vaccinating essential workers first averts slightly more infections. The answer depends partly on what the vaccines do. We know they are very good at preventing illness. We do not yet know how well they stop people passing the virus on.

If the main goal is And the vaccine mostly The stronger case is for
Preventing deaths Prevents serious illness Older and highest-risk people
Preventing infections Prevents transmission People with the most contacts
Reducing unfairness Either Groups with the most exposure and least protection

4. The philosophical fault lines

Behind the policy debate sit some old questions in ethics.

Lives or life-years? A strict focus on saving the most life-years would favour younger people, because each life saved has more years ahead of it. Most frameworks reject that for COVID-19, partly because the risk to the very old is so much higher that it outweighs the difference, and partly because many people find ranking lives by age uncomfortable.

Aggregation. Utilitarian reasoning adds up benefits across people. Critics, from John Rawls onwards, argue that this can ignore what is owed to each individual. A plan that saves the most lives overall but leaves a group that has carried the highest risk all year at the back of the queue may feel unjust even if it is efficient.

Social worth. In the 1960s, a committee in Seattle chose which patients would receive scarce kidney dialysis, partly on the basis of factors such as their job and family situation. It became a famous warning. Modern frameworks are careful to prioritise people because of risk or role, not because some lives are judged more valuable than others.

Simplicity as an ethical value. A complex scheme that tries to weigh every factor may be fairer on paper, but slower to deliver and easier to game. In a pandemic, delay costs lives. That is a moral argument for simple rules such as age bands, not just an administrative one.

5. The global question: vaccine nationalism

The national debates sit inside a larger one. In September, an Oxfam analysis found that wealthy nations representing about 13 percent of the world's population had already bought more than half of the promised doses of the leading vaccine candidates.

From a national point of view, that is understandable. Governments are responsible to their own citizens. From an ethical point of view, it is hard to defend giving a low-risk 30-year-old in a rich country a dose before a health worker or an 85-year-old in a poor one.

Several proposals try to address this. COVAX, co-led by Gavi, the WHO and CEPI, aims to pool purchasing and give countries doses in proportion to population in the first phase. In September, Ezekiel Emanuel and colleagues proposed a "Fair Priority Model" in Science, which would allocate doses between countries in phases, starting with those where vaccines would prevent the most premature deaths. Whether rich countries will share doses before they have vaccinated most of their own populations is one of the big ethical tests of 2021.

6. What this teaches about allocating anything scarce

Most of us will never sit on a vaccine committee. But managers allocate scarce things every week: budget, promotions, training places, interesting projects and their own time. The vaccine debate is an unusually clear example of how to do it well.

Name the goal before the rule

  • "Save the most lives" and "protect those most exposed" lead to different lists. Be honest about which goal you are pursuing.
  • Inside a team, "reward past performance" and "develop future potential" lead to different promotion decisions.

Make the trade-offs explicit

  • Every rule leaves someone waiting. Say who, and why.
  • Separate the factual questions (what will this achieve?) from the moral ones (what do we value?).

Prefer simple, checkable criteria

  • Rules that are easy to understand and hard to game are more likely to be trusted.
  • Leave some room for exceptions, but make the process for exceptions clear.

Be open about the process

  • Publish the reasoning, not just the result. People can accept a decision they disagree with if they can see how it was reached.
  • Involve the people affected where possible.

Revisit as evidence changes

  • If we learn that the vaccines strongly block transmission, the case for prioritising high-contact groups gets stronger. Good allocation rules should say in advance what would change them.

Why this matters

  • Scarcity forces values into the open. When there is not enough to go round, every allocation rule is a statement about what we care about.
  • Efficiency is not the only moral value. Saving the most lives matters enormously, but so do fairness, reciprocity and equal concern.
  • Trust is part of the outcome. A vaccine programme only works if people believe it is fair and come forward to be vaccinated.
  • The global test is still ahead. How rich countries behave in the next year will shape how this pandemic ends and how the next one is handled.

Final Thoughts

Margaret Keenan said yesterday that it was the best early birthday present she could wish for. It is easy to share her joy. Most of us will wait weeks or months for our turn, and that wait is the result of decisions made on our behalf about whose need comes first.

There is no perfect answer to that question. There are only better and worse ways of reaching an answer: honest about the goals, clear about the trade-offs, open to scrutiny and willing to change as evidence comes in. That is true for a national vaccine programme, and it is just as true for the small, everyday decisions about who gets what.

Sources